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13 (28%) patients had CKD stage 3. 6/13 had low predicted risk of
progression at 5 years of whom 4/6 progressed unexpectedly. 1/13 was
identiﬁed as having high risk at 5 years and that 1 patient progressed to
CKD5D/T.
6/18 CKD 3/4 patients with predicted low risk progressed to CKD5D/
T unexpectedly. 1/6 had emergency abdominal surgery, 1/6 patient had
unexplained rapid progression and 4/6 had acute upper gastro-intes-
tinal haemorrhage causing terminal decline of kidney function.
Conclusions: The number of patients analysed was small. The 8-vari-
able equation accurately predicted high risk of progression to CKD5D/T
in 7/9 CKD3/4 patients.
Conversely, 6/18 patients with predicted low risk progressed to
CKD5D/T. Acute medical events including upper gastro-intestinal bleed
accounted for most instances of unexpected progression.
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Introduction: Hypertension is a major risk factor for cardiovascular
disease and is also a risk factor for chronic renal failure. Despite of
advancements in lowering blood pressure, the best approach to lower
it, remains controversial due to the lack of information on its devel-
opment. We therefore, performed plasma proteomics to identify the
markers discriminating hypertensive from normotensives.
Methods: Plasma samples from hypertensive (n=118) and normotensive
subjects (n=85) from the “InGenious Hypercare” cohortwere used for the
study. We performed liquid chromatography online coupled to electro-
spray ionization quadrupole ion trap mass spectrometry for analysis of
the plasma samples. Hypertension speciﬁc plasma peptides were identi-
ﬁed and a model was developed using least absolute shrinkage and se-
lection operator logistic regression. The underlying peptides were
identiﬁed and sequenced ofﬂine using matrix assisted laser desorption
ionization mass spectrometry. Further, to get an insight in to the mech-
anisms, pathway analysis was performed using KEGG and GO databases.
Results: By comparison of plasma samples, 27 biomarkers were iden-
tiﬁed discriminating hypertensives from normotensives. 70% of the
features selected were found to occur less likely in hypertensive pa-
tients. A cross-validated predictor model was developed with the
overall R square of 0.434 and the area under the ROC curve was 0.891
with 95% conﬁdence interval 0.8482 to 0.9349, P<0.0001. The mean
value of the cross-validated predictor score of normotensive and hy-
pertensive patients was found to be -2.007  0.3568 and 3.383 
0.2643, respectively. Phosphtidylinositol 3 kinase regulatory, humanin,
anoctamin 10, NIK related protein kinase, Mannose-6- phospho isom-
erase, tryptophan, erythrocyte membrane glycopeptide, transcription
factor Dp-2, pleckstrin homology domain-containing family O member
1, cardiac phospholamban, osteocalcin or sarcolipin, ras-related protein
Rab-13, protein prune homolog, nexilin and palladin were the identi-
ﬁed peptides. The pathway analysis revealed that these proteins had
mostly cardiac related functions.
Conclusions: Plasma proteomics model was able to predict the hyper-
tensive-normotensive status based on 27 molecular features. After
validation in other cohorts for reproducibility, the identiﬁed markers
may be useful to clarify the causes of hypertension and to predict the
development of hypertension and hence of cardiovascular events.
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Introduction: Genomic technologies enable the rapid and cost-effective
sequencing of DNA and have demonstrated a deﬁnitive diagnosis in
several patient groups. The clinical utility of whole exome sequencing
(WES) in a kidney disease cohort is not yet well established. We
describe the patient characteristics and diagnostic yield of a cohort of
200 patients with suspected genetic kidney disease referred for WES via
a multidisciplinary renal genetics clinic.
Methods: 200 sequential patients were recruited into a prospective
observational cohort study through ﬁve tertiary academic centres in
Victoria, Australia. Patients were referred by their treating nephrolo-
gist to a dedicated renal genetic service funded by the Melbourne
Genomics Health Alliance. Following review by a multidisciplinary
team, consisting of a nephrologist, clinical geneticist and genetic
counsellor, patients were recruited for genomic sequencing, with
analysis for a pre-determined list of genes of interest. We measured the
diagnostic yield and its effect on short term clinical management.
Results: Singleton WES was performed on 123 adult patients and
83 paediatric patients. Majority were female (118) and median age was
27 years (range 0-73 years). 100 of these patients were isolated cases
(77 had a known positive family history). From 104 exome results
available to date (38 paediatric and 66 adults), 43 patients received a
positive molecular diagnosis (41%) and of these 22 (51%) resulted in a
change from the original clinical diagnosis. The diagnostic yield was
greater in the paediatric cohort (53%) compared to the adult cohort
(35%). The effects of genomic testing on clinical management is
currently being analysed.
Conclusions: Singleton WES resulted in a substantial number of posi-
tive diagnoses in both adult and paediatric patients. The ongoing
analysis of this cohort will allow delineation of the sensitivity of exome
sequencing to current diagnostic methods, enable health economic
analysis of testing and facilitate identiﬁcation of the clinical predictors
of a positive diagnosis. To our knowledge, this is the largest prospec-
tive kidney disease cohort to undergo whole exome sequencing with
integrated utility analysis to date.
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Introduction: Chronic kidney disease (CKD) is a substantial cause of
morbidity and mortality worldwide with disproportionate effects in
sub-Saharan Africa (SSA). The optimal methods to accurately estimate
glomerular ﬁltration rate (eGFR) and therefore facilitate identiﬁcation of
CKD among African populations are uncertain. We plan to measure
iohexol excretion and correlate measured GFR with existing equations
to determine the optimal methods to estimate GFR and determine the
prevalence of CKD in Malawi, South Africa and Uganda
Methods: The African Research on Kidney Disease (ARK) study is a
three country study embedded within existing cohorts. We seek to
enrol 3,000 adults >18 years stratiﬁed by eGFR using baseline serum
creatinine. Study procedures include questionnaires on socio-de-
mographics and potential risk factors for kidney disease, anthropom-
etry, body composition, blood pressure, blood chemistry and urine
microscopy and albuminuria. All participants will have a measured GFR
(mGFR) by plasma clearance of iohexol at 120, 180 and 240 minutes.
Blood and urine samples will be bio-banked.
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Results: The eGFR determined by established equations will be
compared with mGFR to establish the most accurate method to estimate
GFR in this population. We will present the population prevalence of
CKD, both overall and stratiﬁed for risk factors of interest, for the three
countries. In addition, our results will provide detailed information
about risk factors associated with CKD in these populations.
Conclusions: The ARK study draws participants from three countries
with harmonised protocols which will increase the applicability of the
ﬁndings across the region and permit identiﬁcation of population dif-
ferences. The study is embedded within established cohorts that have
background information and serial measures that can be used to char-
acterize incidence and progression of CKD. This study will overcome
the limitations of previous research including the use of single creati-
nine measures, small numbers or non-population-based sampling stra-
tegies, and address the lack of data on proteinuria/albuminuria as
recommended by Kidney Disease: Improving Global Outcomes
(KDIGO). The ARK collaboration provides a strong platform for kidney
disease research, within the context of infectious and non-communi-
cable diseases in SSA. Through harmonized study procedures and
sample collection, and pooling of data sets, we hope our results will
contribute to strengthening health systems and informing public health
policy for the screening, prevention and treatment of CKD in the re-
gion. We welcome additional partners from across the continent.
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Introduction: Chronic kidney disease (CKD) is increasing in incidence
globally, and current CKD therapies (angiotensin converting enzyme
inhibitors/ACEi or angiotensin receptor blockers/ARBs) are only
moderately effective, highlighting the need to accelerate research into
new pharmacological approaches. One of the known causes of CKD is
oxidative stress. This project aimed to develop a reliable human pre-
clinical model of oxidative-stress induced CKD to examine the beneﬁts
of adjunct or complementary therapies for CKD treatment.
Methods: Primary human kidney proximal tubular epithelial cells (PTEC)
were isolated from healthy kidney from cancer nephrectomies from con-
senting Royal Brisbane andWomen’s Hospital patients. To develop a CKD
oxidative stress model, PTEC were cultured alone or under low-dose
(0.4mM hydrogen peroxide; H2O2) or high-dose (0.8mM H2O2) oxidizing
conditions over 24h, 48h and 72h. TheACEi Enalaprilwas used at 50 or 500
mM with and without H2O2 in some experiments. PTEC were assessed for
morphology (microscopy and toluidine blue staining), mitochondrial
function (mitochondrial membrane potential; JC-1 staining), mitochondrial
reactive oxygen species (ROS) (MitoSOX dye), proliferation (MTT assay)
and viability (Annexin-V/propidium iodide staining).
Results: Primary human PTEC (n=4) cultured under low-dose oxidizing
conditions displayed reduced proliferation and increased cell death
compared with PTEC cultured alone. This effect was further ampliﬁed
under high-dose oxidizing conditions. Mitochondrial deﬁcit and ROS
production were increased under oxidising conditions. ACEi delivered
with H2O2 improved % of cell proliferation (MTT assay, approximately
65% of controls with 0.4mM H2O2 to 85% with ACEi plus H2O2).
Similarly, membrane potential indicated by JC-1 staining showed
improvement with ACEi.
Conclusions: Use of primary human PTEC for in vitro models of CKD is
likely to produce more relevant data than kidney cell lines that in general
are made up of transformed cultures. Our data suggest that PTEC respond
to oxidative stress in a manner similar to pathogenesis of CKD in human
patients, and that use of Enalapril improves CKD parameters. We will test
whether any synergy is present between established CKD therapies such
as Enalapril and plant-derived extracts currently in use against CKD.
Thus we have established a pre-clinical human model of CKD for future
assessment of novel bioactive (anti-oxidant) compounds as adjunct
therapies to conventional medicines and ultimately translation into
clinical testing in CKD patients.
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Introduction: Despite the development of diagnostic techniques,
methods for predicting changes in renal function or outcomes are still
insufﬁcient. Metabolomics is considered to be a breakthrough method
to address the shortage of tools by analyzing the end metabolites,
reﬂecting genetic and environmental factors. Herein, we would like to
propose the metabolites which signiﬁcantly associated with develop-
ment and progression of chronic kidney disease (CKD).
Methods:We measured urinary metabolites from 1,274 urine samples at
the time of renal biopsy and 147 urine samples from healthy subjects
using nuclear magnetic resonance. The clinical outcome was deﬁned as
a decrease in estimated glomerular ﬁltration ‡ 30%, doubling of serum
creatinine, or development of an end-stage renal disease.
Results: Initial partial components analysis and partial least squares-
discriminant analysis score plots showed discriminated cluster between
CKD and control, and according to the stage of CKD. A total of 41 me-
tabolites conﬁrmed to candidate marker associated with CKD. We took
survival analysis by the median value of each metabolite. There were 9
metabolites (acetone, betaine, choline, dimethylamine, fumarate, glycerol,
lactate, leucine, trimethylamine-N-oxide) which showed signiﬁcantly
increased risk of developing clinical outcomes according to increasing
concentration. In contrary, citrate, and glycine showed decreased risk
according to increasing concentration for developing clinical outcomes.
Total of 8 metabolites (betaine, choline, fumarate, trimethylamine-N-ox-
ide, lactate, leucine, methyl histidine, citrate) revealed signiﬁcantly
different level in concentration in CKD compared to control, moreover
this difference maintained with same way in a different stage of CKD.
Conclusions: Metabolites which inform the disease progression or
development can be a noble biomarker. In our study, betaine, choline,
fumarate, trimethylamine-N-oxide, lactate was revealed as a signiﬁcant
predictor in the progression of CKD. Although additional study for
validation should be performed, we could ﬁnd signiﬁcant metabolites
associate with CKD. And these results could be an instrumental keynote
to moving ahead.
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Introduction: Dyslipidemia has been linked to an increased risk of
cardiovascular morbidity and mortality in patients with chronic kidney
disease (CKD). However, the role of individual lipid parameter in the
development of in the progression of CKD is not well established.
Methods: Among 2,238 patients with non-dialysis CKD enrolled in the
KoreaN cohort study for Outcome in patients With Chronic Kidney
Disease (KNOW-CKD), 1,939 patients who measured total cholesterol
(TC), low density lipoprotein cholesterol (LDL-C), high density lipo-
protein cholesterol (HDL-C), and triglycerides (TG) were included in the
analysis. Study endpoint was a composite of a $ 50% decline in esti-
mated glomerular ﬁltration rate or the onset of end-stage renal disease.
Results: The mean age was 53.8  12.2 years and 1,192 (61.5%) patients
were males. The mean serum concentrations of TC, LDL-C, HDL-C, and
TG were and 174.1  38.9, 96.9  31.3, 49.3  15.5, and 156.6  96.9
mg/dl, respectively. During a median follow-up of 3.0 years, 421 pa-
tients (21.7%) reached the composite end point. In the fully adjusted
multivariable Cox models, HDL-C was signiﬁcantly associated with
increased risk of CKD progression (HR, 1.11 per 10 mg/dl increase;
95% CI, 1.01-1.22; P = 0.03), while TC (HR, 0.99 per 10 mg/dl increase;
95% CI, 0.95-1.03; P = 0.53), LDL-C (HR, 1.01 per 10 mg/dl increase;
95% CI, 0.97-1.06; P = 0.68), and TG (HR, 0.99 per 10 mg/dl increase;
95% CI, 0.98-1.01; P = 0.35) were not. However, areas under the curve
of these 4 lipids were similar and none of the parameters did not
improve the net reclassiﬁcation improvement and the integrated
discrimination improvement for the progression of CKD.
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